Drug intelligence / Profile preview

butylscopolamine bromide

Development stage
Unknown
Lead developer
Quimica Son's
Modality
Small Molecules
Administration
Intravenous, Intramuscular, Subcutaneous
01

Overview

Excosine (also marketed as Excosine-S) is a brand of butylscopolamine bromide (hyoscine butylbromide) developed and marketed by Quimica Son's in Mexico. Butylscopolamine bromide is a peripherally acting antimuscarinic, anticholinergic agent that acts as a competitive antagonist at muscarinic acetylcholine receptors (primarily M3 and M2 subtypes) on smooth muscle cells of the gastrointestinal, biliary, and genitourinary tracts. By blocking acetylcholine-mediated signaling, it reduces smooth muscle contractions and spasms, providing rapid relief from abdominal cramps, colic, and related pain. Because of its quaternary ammonium structure, it does not readily cross the blood-brain barrier, minimizing central nervous system side effects.

Brand names
ExcosineExcosine-S
Other names
bromuro de butilhioscinabutilhioscinabutylscopolaminebutylscopolamine bromidehyoscine butylbromidehyoscine N-butylbromideN-butylscopolammonium bromidescopolamine butylbromidescopolamine N-butylbromide
02

Targets

M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)CHRM4 (M4)CHRM5 (M5)Nicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on butylscopolamine bromide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on butylscopolamine bromide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call